サラセミア診断市場-世界の産業規模、シェア、動向、機会、予測、2018～2028年、タイプ別、エンドユーザー別、地域別、競合

世界のサラセミア診断市場は、医療費の増加、政府の支援政策、診断技術の進歩、サラセミアに対する意識の高まり、サラセミアの有病率の増加により、2028年の予測期間中に大きく成長すると予測されています。

サラセミアは、体内の酸素輸送に不可欠なヘモグロビンの生産に影響を及ぼす遺伝的血液疾患です。サラセミアには、主にαサラセミアとβサラセミアの2種類があります。

世界のサラセミア診断市場は、世界のサラセミアの有病率の増加と、この病気に対する人々の意識の高まりによって牽引されています。キュアス社の発表した報告書によると、世界人口の約1.5％、約1億人がB型サラセミアの遺伝子を持っており、東南アジア、中東、地中海地域で最も有病率が高いです。サラセミア診断市場には、サラセミアのスクリーニング、診断、モニタリングのための検査が含まれます。これらの検査には、全血球算定、ヘモグロビン電気泳動、DNA分析、その他が含まれます。世界のサラセミア診断市場は、サラセミアの検出においてより高い精度と感度を提供するPCRや遺伝子検査などの高度な診断技術の採用が増加していることから、成長が見込まれています。

地理的には、アジア太平洋と中東・北アフリカ地域がサラセミア診断市場を独占しています。しかし、北米や欧州、特にトルコのような他の地域でも、サラセミアに対する意識の高まりと高度な診断技術の利用可能性により、市場は成長しています。従って、世界のサラセミア診断市場の需要は予測期間中に上昇すると予想されます。

サラセミアに対する意識の高まりが世界のサラセミア診断市場の需要を促進

サラセミアは、世界中で数百万人が罹患している遺伝性血液疾患です。血液中の酸素運搬を担うタンパク質であるヘモグロビンの生成を制御する遺伝子の変異によって引き起こされます。サラセミア患者は健康な赤血球の産生が少ないため、貧血、疲労、その他の合併症を発症するリスクが高いです。この疾患は、遺伝子変異が多い地中海沿岸、中東、アジアの国々で特に多くみられます。世界全体では、年間約30～40万人の子供が遺伝的な実質的Hb疾患を持って生まれており、そのうち約8,000万人がB型サラセミアであると推定されています。

有利な政府政策がサラセミア診断市場成長の促進要因

支援的な政府政策は、世界のサラセミア診断市場の需要に影響を与える原動力となっています。世界中の政府は、医療システムにおけるサラセミアの負担増に対処する必要性を認識しており、サラセミア診断検査の開発と使用を支援する措置を講じています。サラセミア患者は健康な赤血球の産生が少なく、貧血、疲労、その他の合併症を発症するリスクが高いです。この疾患は、遺伝子変異が多い地中海沿岸、中東、アジアの国々で特に多く見られます。

政府の支援政策がサラセミア診断検査の需要に影響を与えた主な方法は、資金と投資です。各国政府はサラセミア診断検査の研究開発に投資し、より正確で効率的な検査を開発してきました。各国政府はまた、特にサラセミアの有病率が高い新興諸国において、診断検査へのアクセスを向上させるために資金を提供してきました。例えば、サウジアラビアでは、近々結婚を予定しているカップルが、遺伝性血液疾患（鎌状赤血球貧血やサラセミア、鎌状赤血球貧血など）や感染症（B型肝炎、C型肝炎、HIV/AIDSなど）をチェックするために、いくつかの検査を受ける必要がある「婚前スクリーニング」が実施されています。

政府はまた、サラセミアのスクリーニングを義務付ける政策を実施しています。例えば、多くの国では、新生児にサラセミアのスクリーニングを行い、早期にサラセミア患者を特定し、適切な治療を提供しています。これにより、サラセミア診断検査に対する需要が高まり、正確で信頼性の高い検査の必要性が高まっています。重症型のサラセミア（大発性サラセミアなど）の子供は通常5歳未満で死亡し、サラセミア患者の平均余命は約30年で、主に深刻な資源不足の国々で見られます。

さらに、政府の支援政策が、サラセミアと早期診断・治療の重要性に対する認識を高めるのに役立っています。各国政府は、サラセミアとその個人および社会への影響について国民を教育するための啓発キャンペーンを開始しました。これにより、サラセミアの診断検査を希望する人の数が増加し、この疾患に関連する偏見を減らすのに役立っています。

診断技術の進歩がサラセミア診断市場の成長需要を牽引

診断技術の進歩は、市場におけるサラセミア診断検査の需要を促進する上で重要な役割を果たしています。これらの進歩により、より正確で効率的な検査が開発され、サラセミア患者のケアの質が向上しています。遺伝子検査は、サラセミアを含む多くの遺伝性疾患の診断と管理に革命をもたらしました。この検査では、個人のDNAを分析して、疾患に関連する特定の遺伝子変異を特定します。この種の検査は非常に正確で、症状を示さない人でもサラセミアを検出することができます。ポイント・オブ・ケア検査（POCT）により、ベッドサイドや診察室で迅速に病気を診断することができます。POCT装置は持ち運びが可能で、数分で結果を出すことができるため、検査室での検査の必要性を減らし、患者のケアを向上させることができます。

企業プロファイル

Hybribio Limited、Oasis Diagnostics Corporation、ViennaLab Diagnostics GmbH、GENETEK BIOPHARMA GmbH、Devyser Diagnostics AB、Yaneng BIOscience（Shenzhen）Co.Ltd.、Bio-Rad Laboratories, Inc.は、世界のサラセミア診断市場における主要企業の一部です。

調査範囲

本レポートでは、世界のサラセミア診断市場を以下のカテゴリーに分類し、さらに業界動向についても詳述しています：

サラセミア診断市場：タイプ別

• 完全血球（CBC）検査
• ヘモグロビン検査
• 鉄欠乏検査
• DNA検査
• その他

サラセミア診断市場：エンドユーザー別

• 病院・クリニック
• 診断研究所
• その他

サラセミア診断市場：地域別

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• ドイツ
• フランス
• 英国
• スペイン
• イタリア
• アジア太平洋
• 中国
• インド
• マレーシア
• タイ
• ベトナム
• 南米
• ブラジル
• アルゼンチン
• 中東・アフリカ
• エジプト
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦
• トルコ
• クウェート
• カタール
• バーレーン

競合情勢

• 企業プロファイル：世界のサラセミア診断市場に参入している主要企業の詳細分析

利用可能なカスタマイズ：

• TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です。

企業情報

• 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 COVID-19が世界のサラセミア診断市場に与える影響

第6章 臨床試験分析

第7章 臨床試験分析世界のサラセミア診断市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • タイプ別（完全血球（CBC）検査、ヘモグロビン検査、鉄欠乏検査、DNA検査、その他）
  • エンドユーザー別（病院・クリニック、診断研究所、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • タイプ別
  • エンドユーザー別
  • 地域別

第8章 北米のサラセミア診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第9章 欧州のサラセミア診断市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • イタリア

第10章 アジア太平洋のサラセミア診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • マレーシア
  • タイ
  • ベトナム

第11章 南米のサラセミア診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン

第12章 中東・アフリカのサラセミア診断市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • エジプト
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • トルコ
  • クウェート
  • カタール
  • バーレーン

第13章 市場力学

• 促進要因
• 課題

第14章 市場動向と発展

• 製品上市
• 合併と買収

第15章 世界のサラセミア診断市場：SWOT分析

第16章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第17章 競合情勢

• Hybribio Limited
• Oasis Diagnostics Corporation
• ViennaLab Diagnostics GmbH
• GENETEK BIOPHARMA GmbH
• Devyser Diagnostics AB
• Yaneng BIOscience（Shenzhen）Co., Ltd.
• BioLab Diagnostics India Private Limited
• NPT Co. Ltd.
• Bio-Rad Laboratories, Inc.

第18章 戦略的提言

第19章 調査会社について・免責事項

Global Thalassemia Diagnostic market is anticipated to grow considerably in the forecast period of 2028 due to rising healthcare expenditure, supportive government policy, advancements in diagnostic technologies, growing awareness about thalassemia, and increasing prevalence of thalassemia.

Thalassemia is a genetic blood disorder that affects the production of hemoglobin, which is essential for the transportation of oxygen in the body. There are two main types of thalassemia: alpha thalassemia and beta thalassemia.

The market for global thalassemia diagnostics is driven by the increasing prevalence of thalassemia worldwide, coupled with growing awareness among people about the disease. According to a published report by Cureus, around 1.5% of the world's population, or about 100 million people, carry the genes for B-thalassemia, with the highest prevalence in Southeast Asia, the Middle East, and the Mediterranean region. The market for thalassemia diagnostics includes tests for screening, diagnosis, and monitoring of thalassemia. These tests include complete blood count, hemoglobin electrophoresis, DNA analysis, and others. The global thalassemia diagnostics market is expected to grow due to the increasing adoption of advanced diagnostic technologies, such as PCR and genetic testing, which offer higher accuracy and sensitivity in detecting thalassemia.

Geographically, the Asia Pacific and MENA regions dominate the thalassemia diagnostic market, owing to the high prevalence of thalassemia in the region. However, the market is also growing in other regions, such as North America and Europe especially in Turkey, due to increasing awareness about thalassemia and the availability of advanced diagnostic technologies. Therefore, it is expected that the demand for the global thalassemia diagnostic market is going to rise in the forecast period.

Growing Awareness About Thalassemia is Propelling the Demand for the Global Thalassemia Diagnostic Market

Thalassemia is a genetic blood disorder that affects millions of people worldwide. It is caused by mutations in the genes that control the production of hemoglobin, a protein that is responsible for carrying oxygen in the blood. Individuals with thalassemia produce fewer healthy red blood cells and are therefore at a higher risk of developing anemia, fatigue, and other complications. The disorder is particularly prevalent in countries around the Mediterranean, Middle East, and Asia, where gene mutations are more usual. Globally, it is estimated that approximately 300-400 thousand children are born yearly with genetic substantial Hb diseases of which around 80 million children are transferors of B-thalassemia.

Growing awareness about thalassemia is propelling the demand for the global thalassemia diagnostic market. There is an increasing understanding of the disease among people, which has led to an increase in the number of people seeking diagnostic tests for thalassemia. The awareness has also increased the number of newborns and pregnant women being screened for thalassemia, which has further driven the demand for diagnostic tests.

The efforts of governments and healthcare organizations to educate people about the disease are one of the main drivers of the growing awareness about thalassemia. Governments around the world have launched awareness campaigns to educate people about the importance of early detection and treatment of thalassemia. These campaigns have included public service announcements, seminars, and workshops for healthcare professionals and the public. Such as Turkey Hemoglobinopathy Control Program has been initiated in 33 provinces of Turkey to screen and create awareness about B-thalassemia and its symptoms.

In addition to government initiatives, healthcare organizations, and patient advocacy groups have also played a significant role in raising awareness about thalassemia. These organizations have provided information about the disease to patients and their families, as well as to healthcare professionals. They have also offered support and resources to individuals with thalassemia and their families. The FDA or the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to Beta Thalassemia drugs. Through this ODD, companies can get incentives to invest in rare disease treatments.

Another factor contributing to the growing awareness about thalassemia is the availability of information on the internet. Patients and their families can access information about the disease, including its symptoms, causes, and treatment options. The internet has also provided a platform for patient communities to connect and share their experiences, which has helped to increase awareness about the disease.

The growing awareness about thalassemia has led to an increase in the demand for thalassemia diagnostic tests. Diagnostic tests for thalassemia include blood tests, DNA analysis, and hemoglobin electrophoresis. These tests are used to screen, diagnose, and monitor the disease. With increased awareness about the disease, more people are seeking diagnostic tests, which has driven the demand for thalassemia diagnostic tests. Therefore, all these factors are expected to drive the demand for the global thalassemia diagnostic market in the forecast period.

Favorable Government Policies are Key drivers that Drive the Thalassemia Diagnostic Market Growth

Supportive government policies have been a driving force in influencing the demand for the global thalassemia diagnostic market. Governments around the world have recognized the need to address the increasing burden of thalassemia on their healthcare systems and have taken steps to support the development and use of thalassemia diagnostic tests. Individuals with thalassemia produce fewer healthy red blood cells and are at a higher risk of developing anemia, fatigue, and other complications. The disorder is particularly prevalent in countries around the Mediterranean, Middle East, and Asia, where the gene mutations are more common.

The primary method by which supportive government policies have influenced the demand for thalassemia diagnostic tests is through funding and investment. Governments have invested in research and development of new and improved diagnostic tests for thalassemia, which has led to the development of more accurate and efficient tests. Governments have also provided funding to increase access to diagnostic tests, particularly in developing countries where the prevalence of thalassemia is high. For instance, the "Premarital Screening" in which a couple planning to get married soon needs to undergo several tests to check genetic blood disorders (e.g. sickle cell anemia and thalassemia and sickle cell anemia) and infectious diseases (e.g. hepatitis B, hepatitis C, and HIV/AIDS) in Saudi Arabia.

Governments have also implemented policies that require mandatory screening for thalassemia. For example, in many countries, newborns are screened for thalassemia to identify those with the disorder early on and provide appropriate treatment. This has increased the demand for thalassemia diagnostic tests and has led to a greater need for accurate and reliable tests. Children with severe forms of thalassemia (such as thalassemia major) typically decease under 5 years of age and the average life expectancy of patients suffering from thalassemia is about 30 years, predominantly in seriously resource-constrained countries.

Furthermore, supportive government policies have helped to increase awareness about thalassemia and the importance of early diagnosis and treatment. Governments have launched awareness campaigns to educate the public about thalassemia and its impact on individuals and society. This has led to an increase in the number of people seeking diagnostic tests for thalassemia and has helped to reduce the stigma associated with the disorder.

Advancements in Diagnostic Technologies are Driving the Demand for Thalassemia Diagnostic Market Growth

Advancements in diagnostic technologies have played a significant role in driving the demand for thalassemia diagnostic tests in the market. These advancements have led to the development of more accurate and efficient tests, which have improved the quality of care for individuals with thalassemia. Genetic testing has revolutionized the diagnosis and management of many genetic disorders, including thalassemia. It involves analyzing an individual's DNA to identify specific genetic mutations associated with the disorder. This type of testing is highly accurate and can detect thalassemia even in individuals who do not exhibit symptoms. Point-of-care testing (POCT) allows for the rapid diagnosis of disease at the bedside or in the doctor's office. POCT devices are portable and can provide results in a matter of minutes, reducing the need for laboratory testing and improving patient care.

Market Segmentation

Global Thalassemia Diagnostic market is segmented based on type, end-user, and region. Based on type, the market is segmented into complete blood cell (CBC) tests, hemoglobin tests, iron deficiency tests, DNA tests, and others. Based on end-user, the market is fragmented into hospitals & clinics, diagnostic laboratories, and others. Based on region, the market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Hybribio Limited, Oasis Diagnostics Corporation, ViennaLab Diagnostics GmbH, GENETEK BIOPHARMA GmbH, Devyser Diagnostics AB, Yaneng BIOscience, Shenzhen) Co., Ltd., BioLab Diagnostics India Private Limited, NPT Co. Ltd., and Bio-Rad Laboratories, Inc. are some of the key players in the global thalassemia diagnostic market.

Report Scope:

In this report, global thalassemia diagnostic market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Thalassemia Diagnostic Market, By Type:

• Complete Blood Cell (CBC) Test
• Hemoglobin Test
• Iron Deficiency Test
• DNA Tests
• Others

Thalassemia Diagnostic Market, By End User:

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Thalassemia Diagnostic Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Asia-Pacific
• China
• India
• Malaysia
• Thailand
• Vietnam
• South America
• Brazil
• Argentina
• Middle East & Africa
• Egypt
• South Africa
• Saudi Arabia
• UAE
• Turkey
• Kuwait
• Qatar
• Bahrain

Competitive landscape

• Company Profiles: Detailed analysis of the major companies present in the global Thalassemia Diagnostic market.

Available Customizations:

• With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Thalassemia Diagnostics Market

6. Clinical Trial Analysis

• 6.1. Ongoing Clinical Trials
• 6.2. Completed Clinical Trials
• 6.3. Terminated Clinical Trials
• 6.4. Breakdown of Pipeline, By Development Phase
• 6.5. Breakdown of Pipeline, By Status
• 6.6. Breakdown of Pipeline, By Study Type
• 6.7. Breakdown of Pipeline, By Region
• 6.8. Clinical Trials Heat Map

7. Global Thalassemia Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Complete Blood Cell (CBC) Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others)
  • 7.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 7.2.3. By Region
  • 7.2.4. By Company (2022)
• 7.3. Market Map
  • 7.3.1. By Type
  • 7.3.2. By End User
  • 7.3.3. By Region

8. North America Thalassemia Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Thalassemia Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By End User
  • 8.3.2. Canada Thalassemia Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Mexico Thalassemia Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By End User

9. Europe Thalassemia Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Europe: Country Analysis
  • 9.3.1. Germany Thalassemia Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By End User
  • 9.3.2. France Thalassemia Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By End User
  • 9.3.3. United Kingdom Thalassemia Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By End User
  • 9.3.4. Spain Thalassemia Diagnostics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By End User
  • 9.3.5. Italy Thalassemia Diagnostics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Type
      • 9.3.5.2.2. By End User

10. Asia-Pacific Thalassemia Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. Asia-Pacific: Country Analysis
  • 10.3.1. China Thalassemia Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By End User
  • 10.3.2. India Thalassemia Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By End User
  • 10.3.3. Malaysia Thalassemia Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By End User
  • 10.3.4. Thailand Thalassemia Diagnostics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By End User
  • 10.3.5. Vietnam Thalassemia Diagnostics Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Type
      • 10.3.5.2.2. By End User

11. South America Thalassemia Diagnostics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Type
  • 11.2.2. By End User
  • 11.2.3. By Country
• 11.3. South America: Country Analysis
  • 11.3.1. Brazil Thalassemia Diagnostics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Type
      • 11.3.1.2.2. By End User
  • 11.3.2. Argentina Thalassemia Diagnostics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Type
      • 11.3.2.2.2. By End User

12. Middle East and Africa Thalassemia Diagnostics Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Type
  • 12.2.2. By End User
  • 12.2.3. By Country
• 12.3. MEA: Country Analysis
  • 12.3.1. Egypt Thalassemia Diagnostics Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Type
      • 12.3.1.2.2. By End User
  • 12.3.2. South Africa Thalassemia Diagnostics Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Type
      • 12.3.2.2.2. By End User
  • 12.3.3. Saudi Arabia Thalassemia Diagnostics Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Type
      • 12.3.3.2.2. By End User
  • 12.3.4. UAE Thalassemia Diagnostics Market Outlook
    • 12.3.4.1. Market Size & Forecast
      • 12.3.4.1.1. By Value
    • 12.3.4.2. Market Share & Forecast
      • 12.3.4.2.1. By Type
      • 12.3.4.2.2. By End User
  • 12.3.5. Turkey Thalassemia Diagnostics Market Outlook
    • 12.3.5.1. Market Size & Forecast
      • 12.3.5.1.1. By Value
    • 12.3.5.2. Market Share & Forecast
      • 12.3.5.2.1. By Type
      • 12.3.5.2.2. By End User
  • 12.3.6. Kuwait Thalassemia Diagnostics Market Outlook
    • 12.3.6.1. Market Size & Forecast
      • 12.3.6.1.1. By Value
    • 12.3.6.2. Market Share & Forecast
      • 12.3.6.2.1. By Type
      • 12.3.6.2.2. By End User
  • 12.3.7. Qatar Thalassemia Diagnostics Market Outlook
    • 12.3.7.1. Market Size & Forecast
      • 12.3.7.1.1. By Value
    • 12.3.7.2. Market Share & Forecast
      • 12.3.7.2.1. By Type
      • 12.3.7.2.2. By End User
  • 12.3.8. Bahrain Thalassemia Diagnostics Market Outlook
    • 12.3.8.1. Market Size & Forecast
      • 12.3.8.1.1. By Value
    • 12.3.8.2. Market Share & Forecast
      • 12.3.8.2.1. By Type
      • 12.3.8.2.2. By End User

13. Market Dynamics

• 13.1. Drivers
• 13.2. Challenges

14. Market Trends & Developments

• 14.1. Product Launches
• 14.2. Mergers & Acquisitions
• 14.3. Recent Developments

15. Global Thalassemia Diagnostics Market: SWOT Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. Business Overview
• 17.2. Company Snapshot
• 17.3. Products & Services
• 17.4. Financials (In case of listed companies)
• 17.5. Recent Developments
• 17.6. SWOT Analysis
  • 17.6.1. Hybribio Limited
  • 17.6.2. Oasis Diagnostics Corporation
  • 17.6.3. ViennaLab Diagnostics GmbH
  • 17.6.4. GENETEK BIOPHARMA GmbH
  • 17.6.5. Devyser Diagnostics AB
  • 17.6.6. Yaneng BIOscience (Shenzhen) Co., Ltd.
  • 17.6.7. BioLab Diagnostics India Private Limited
  • 17.6.8. NPT Co. Ltd.
  • 17.6.9. Bio-Rad Laboratories, Inc.

18. Strategic Recommendations

19. About Us & Disclaimer